Prostate Cancer Prospective Cohort
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Prostate Cancer Prospective Cohort|
- Ability to recognize increased risk of metastatic prostate cancer based on specific genetic polymorphisms. [ Time Frame: At the time of prostate cancer diagnosis ]
- Ability to predict risk for treatment failure based on analysis of specific polymorphisms. [ Time Frame: At the time of prostate cancer diagnosis ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||May 2000|
|Estimated Study Completion Date:||June 2018|
|Estimated Primary Completion Date:||June 2018 (Final data collection date for primary outcome measure)|
Newly diagnosed patients
Patients with newly diagnosed prostate cancer.
DNA will be isolated from each person and then studied for the presence of certain genes that may increase the chance of developing prostate cancer. Certain genes will also be studied in patients with known prostate cancer to determine if they increase the chance of cancer spreading to other parts of the body and decrease one's chance of being cured. Small differences in genes can slightly affect their ability to function. While these differences are normal, they may influence the way the cancer responds to therapy. An understanding of which genes increase (or decrease) the chance of being cured of a disease, such as prostate cancer, will improve our ability to take care of patients more effectively.
A second purpose of this study is to collect blood and cancer tissue for future studies. While the small differences in genes may be the best marker of bad cancer, it is also possible that proteins in blood or tumor may be a better marker.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00937586
|Contact: Aleksandra P Klim, RN||(314) 747-9781|
|United States, Missouri|
|Washington University School of Medicine||Recruiting|
|St. Louis, Missouri, United States, 63110|
|Contact: Aleksandra P. Klim, RN 314-747-9781|
|Principal Investigator:||Bettina Drake, PhD||Washington University School of Medicine|